BioCardia Advances FDA Pathway for Helix Cardiac Delivery Catheter
Event summary
- BioCardia completed a Pre-Submission to the FDA under its Q-Submission program for the Helix Transendocardial Delivery Catheter on February 10, 2026.
- The submission is supported by data from 15 clinical trials across three primary cardiac indications.
- FDA clearance of Helix could streamline future approvals for BioCardia’s cell therapies for heart failure and chronic myocardial ischemia.
- The Helix catheter is designed for precise, minimally invasive delivery of therapeutic and diagnostic agents to the heart.
The big picture
BioCardia’s Pre-Submission for the Helix catheter marks a critical step in the regulatory pathway for advanced cardiac therapies. The approval, if granted, could position Helix as the first transendocardial delivery catheter system in the U.S., potentially reducing development risk for partners and accelerating the approval of BioCardia’s cell therapies. This aligns with broader industry trends toward minimally invasive, targeted treatments for cardiovascular diseases.
What we're watching
- Regulatory Timing
- Whether the FDA will align on the regulatory pathway and timing for approval within the next 45 days.
- Market Clearance
- The pace at which BioCardia can secure market clearance following FDA alignment.
- Partnership Potential
- How FDA approval of Helix will affect BioCardia’s ability to attract biopharmaceutical and biotechnology partners.
Related topics